Skip to main content
. 2018 Oct 29;27(4):1459–1469. doi: 10.1007/s00520-018-4481-x

Fig. 1.

Fig. 1

Adherence to EORTC and ASCO G-CSF guidelines to reduce the incidence of febrile neutropenia after chemotherapy by center certification (OnkoZert/DGHO/CCC). FN febrile neutropenia; OR odds ratio; Pearson’s chi-squared test, p values adjusted using the Benjamini and Hochberg procedure to control the false discovery rate (FDR)